MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
0.6868
-0.0330
-4.58%
After Hours: 0.8399 +0.1531 +22.29% 16:33 06/10 EDT
OPEN
0.6900
PREV CLOSE
0.7198
HIGH
0.7200
LOW
0.6633
VOLUME
66.41K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
0.4912
MARKET CAP
63.86M
P/E (TTM)
-1.4675
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (0601-0605)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Citius Oncology (CTOR)
TipRanks · 06/03 16:50
Most and least shorted healthcare stocks with market cap up to $2B at the end of May
Seeking Alpha · 06/03 13:45
Citius Oncology Highlights Promising LYMPHIR Combo Phase 1 Data
TipRanks · 06/01 22:41
Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO
TipRanks · 06/01 12:16
Weekly Report: what happened at CTOR last week (0525-0529)?
Weekly Report · 06/01 10:27
Citius Oncology registers to sell 32.93M shares of common stock for holders
TipRanks · 05/29 20:41
Buy Rating Reaffirmed on Lymphir’s Promising Early Data; $4 Price Target Maintained
TipRanks · 05/27 19:25
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.